Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.2584
+0.00532.09%
Post-market: 0.2567-0.0017-0.66%19:48 EDT
Volume:877.27K
Turnover:227.30K
Market Cap:7.87M
PE:-0.07
High:0.2700
Open:0.2631
Low:0.2540
Close:0.2531
52wk High:2.98
52wk Low:0.1901
Shares:30.44M
Float Shares:28.51M
Volume Ratio:0.71
T/O Rate:3.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:1.02
PE(LYR):-0.01

Loading ...

Silver Bullet Data Services Wins Shareholder Backing to Delist from AIM and Go Private

TIPRANKS
·
Jun 25

EPE Special Opportunities Increases Treasury Stock with AIM Share Buyback

TIPRANKS
·
Jun 25

CPP Group to Delist from AIM and Raise £5m to Support Blink Parametric

TIPRANKS
·
Jun 25

Hargreave Hale AIM VCT Cuts Share Count with Targeted Buyback

TIPRANKS
·
Jun 25

Maven Renovar VCT wins full AGM backing for AIM Plus strategy shift

TIPRANKS
·
Jun 24

Gana Media Director Increases Stake with AIM Share Purchase

TIPRANKS
·
Jun 24

AIM Immunotech Completes Phase 2 Duripanc Trial Enrollment for Ampligen-imfinzi in Metastatic Pancreatic Cancer

Reuters
·
Jun 24

AIM Immunotech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

THOMSON REUTERS
·
Jun 24

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

GlobeNewswire
·
Jun 24

Blow to AIM as pawnbroker Ramsdens snapped up by US giant for £206m

cityam
·
Jun 23

M.P. Evans cuts share count with latest buyback on AIM

TIPRANKS
·
Jun 23

Vast Resources Extends Reverse Takeover Deadline as AIM Suspension Continues

TIPRANKS
·
Jun 23

Talon Resources Debuts on AIM as North American Gold Explorer with Eagle Lake Focus

TIPRANKS
·
Jun 23

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

GlobeNewswire
·
Jun 22

Restore plc Cancels 104,000 Shares After AIM Buyback

TIPRANKS
·
Jun 22

RentGuarantor Raises £1m in AIM Placing as Founder Trims Stake

TIPRANKS
·
Jun 20

B90 Chairman Increases Stake with AIM Share Purchase

TIPRANKS
·
Jun 19

Octopus AIM VCT 2 Cuts Share Count After Buyback, Updates Voting Rights

TIPRANKS
·
Jun 18

BRIEF-Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027

Reuters
·
Jun 18

AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient

MT Newswires Live
·
Jun 18